Physician profile
Yelena R Drexler
NPI 1225354186
$42,848.08
in general payments reported to CMS, 2019-2025
10 companies · $40K in 2025
The $40K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.47 · 2022: $20.74 · 2024: $3,184 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Travel and Lodging: $3,510 · Food and Beverage: $1,866 · Education: $69.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,312.52 |
| Travel and Lodging | $3,509.93 |
| Food and Beverage | $1,865.70 |
| Education | $69.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $27,886.78 | 2024-2025 | Filspari |
| Genentech USA, INC. | $6,688.47 | 2025 | Gazyva |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,409.43 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $1,965.73 | 2024 | |
| Alexion Pharmaceuticals, INC. | $1,732.88 | 2025 | |
| Opko Pharmaceuticals, LLC | $69.47 | 2019 | |
| Ani Pharmaceuticals, INC. | $46.45 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $28.13 | 2024 | Renal - Acute |
| Genentech, INC. | $20.74 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yelena Drexler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.